Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

Stephanie Gomez / nature - Nature Medicine, Published online: 30 June 2026; doi:10.1038/s41591-026-04449-9In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with o…

AI Summary: A phase I trial of multi‑antigen‑targeted T cells for aggressive pediatric CNS tumors reported early survival and safety signals, suggesting these engineered cells can engage heterogeneous tumor antigens. Investigators emphasize cautious optimism: encouraging early responses in a dire setting, but longer follow‑up and larger cohorts are needed before this becomes standard‑of‑care.